This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant neoplasm of thyroid gland (thyroid cancer)Malignant Neoplasm of Thyroid Gland

Contents
A. Classification codes | B. Synonyms | C. Adult onset
1. History | 2. Causes | 3. Genetics | 4. General epidemiology | 5. Pathophysiology
6. Symptoms | 7. Signs | 8. Screening | 9. Diagnosis | 10. Treatment
11. Prognosis | 12. Prevention | 13. References
ItemDetails
A. Classification codesICD-10: C73 | Special Copayment Reduction: V193 | Copayment 5% (for 5 years from the date of cancer patient registration)
B. SynonymsThyroid cancer, papillary thyroid cancer, follicular thyroid cancer, medullary thyroid cancer, anaplastic thyroid cancer, Papillary thyroid carcinoma (PTC), Follicular thyroid carcinoma (FTC), Medullary thyroid carcinoma (MTC), Anaplastic thyroid carcinoma (ATC), Hurthle cell carcinoma
C. Adult onsetVery high — occurs mainly in adults in their 30s–60s; papillary thyroid cancer is female-predominant; medullary thyroid cancer is associated with MEN2; anaplastic thyroid cancer occurs mainly in the 60s–70s

1. History

Records of thyroid disease date back to ancient China (around 3000 BC) and ancient Egyptian medicine, and goiter due to iodine deficiency has long afflicted humankind. Research on thyroid cancer in the modern sense began in the late 19th century with advances in thyroid surgical technique. In 1883, the Swiss surgeon Theodor Kocher established the safety of total thyroidectomy and received the 1909 Nobel Prize in Physiology or Medicine for this achievement. Kocher's work became the cornerstone of surgical treatment for thyroid cancer.

In the 20th century, the histologic classification of thyroid cancer was established. In the 1940s–60s, the distinction of the 4 main histologic types—papillary, follicular, medullary and anaplastic—was established. The 1986 Chernobyl nuclear power plant accident became a natural experiment that epidemiologically demonstrated a strong association between radioactive iodine (I-131) exposure and the development of papillary thyroid cancer—after the accident, papillary thyroid cancer in children in contaminated areas increased dozens-fold. In Korea, the spread of ultrasound-guided fine-needle aspiration biopsy (US-guided FNA) and thyroid ultrasound screening in the late 1990s caused a sharp rise in thyroid cancer incidence, which became the background to the controversy over the world's highest thyroid cancer screening rate. K-TIRADS (Korean Thyroid Imaging Reporting and Data System) was revised and published in 2021 and became the standard for evaluating thyroid nodules.

2. Causes

Ionizing radiation exposure is the strongest established environmental risk factor for thyroid cancer. Childhood head and neck radiotherapy (formerly used to treat thymic enlargement and tonsillar enlargement), inhalation of radioactive iodine from nuclear accidents (Chernobyl, Fukushima), and head and neck irradiation for cancer treatment all markedly increase the risk of thyroid cancer—especially papillary thyroid cancer. The risk is greater the younger the age at exposure and the higher the radiation dose. Iodine intake is also associated with histologic type. Follicular and anaplastic thyroid cancers are relatively common in iodine-deficient areas, and the proportion of papillary thyroid cancer is high in iodine-sufficient (or excess-supply) areas.

Genetic factors are important. Twenty-five percent of medullary thyroid cancers are hereditary, arising in multiple endocrine neoplasia type 2 (MEN2A: mainly Cys634Arg; MEN2B: mainly Met918Thr) caused by germline mutations of the RET proto-oncogene (ret proto-oncogene). Family history is also a risk factor for papillary thyroid cancer, and the risk of thyroid cancer is increased in patients with PTEN hamartoma syndrome (Cowden syndrome) and familial adenomatous polyposis (FAP). Women are affected about 3–4 times more often than men, and there is a hypothesis that estrogen may promote thyroid cell growth.

3. Genetics

The molecular genetics of thyroid cancer differ distinctly by histologic type, which is the key basis for targeted therapy strategies. The most common molecular abnormality in papillary thyroid cancer (PTC) is the BRAF V600E mutation (79.4% of Korean PTC), which activates the MAPK pathway. RET/PTC rearrangements (RET1, RET3) are particularly common in radiation-related PTC. RAS mutations (HRAS, NRAS, KRAS) are observed in follicular variant PTC and follicular carcinoma. NTRK (TRK) fusions are found in 5–15% of PTC and are therapeutic targets of TRK inhibitors such as larotrectinib and entrectinib.

PAX8-PPARγ rearrangement and RAS mutations are characteristic of follicular thyroid cancer (FTC). In medullary thyroid cancer (MTC), RET proto-oncogene mutations (germline and somatic) are central, and selpercatinib and pralsetinib have received FDA approval for RET variant/fusion-positive thyroid cancer. In anaplastic thyroid cancer (ATC), BRAF V600E mutation (about 45%), TP53 variants, PI3K/AKT/mTOR pathway abnormalities and TERT promoter variants are frequent. In BRAF V600E-positive ATC, dabrafenib+trametinib combination therapy showed a 56% response rate and received FDA approval. MGMT promoter methylation and MSI testing are also used in ATC to predict response to immune checkpoint inhibitors.

4. General epidemiology

Korea is one of the countries with the highest thyroid cancer incidence in the world, a phenomenon mainly attributable to the explosive spread of ultrasound screening. From 1993 to 2011, thyroid cancer incidence in Korea increased about 15-fold, and in 2011 it ranked first among all cancers in women. This period coincides with the time when thyroid ultrasound was included in government-led cancer screening programs or widely performed as a non-covered service. The age-standardized incidence of thyroid cancer in Korean women was among the highest in the world, but thyroid cancer mortality changed little, raising controversy over overdiagnosis.

Ninety-five percent of thyroid cancers in Korea are papillary thyroid cancer, with follicular about 3%, medullary about 1%, and anaplastic less than about 1%. Worldwide, papillary thyroid cancer also accounts for about 85–90%. Anaplastic thyroid cancer accounts for only 1–2% of all thyroid cancers but is an extremely lethal cancer accounting for about 40–50% of thyroid cancer deaths. Medullary thyroid cancer accounts for about 3–5% of thyroid cancers, and 25% are hereditary (MEN2). The female predominance of thyroid cancer (female:male = 3–4:1) is common worldwide.

5. Pathophysiology

The pathophysiology of thyroid cancer follows different molecular pathways depending on histologic type. In papillary thyroid cancer, the main oncogenic mechanism is activation of the MAPK (RAS-RAF-MEK-ERK) signaling pathway. BRAF V600E mutation → constitutive activation of MEK-ERK → promotion of cell proliferation and suppression of differentiation. RET/PTC rearrangements also activate the same pathway. RAS mutations simultaneously activate the MAPK and PI3K-Akt pathways and are common in follicular variant PTC and some FTC. In radiation-induced PTC, RET/PTC rearrangements arise as a result of radiation-induced DNA double-strand breaks → inappropriate rejoining.

In medullary thyroid cancer, RET proto-oncogene mutation → constitutive activation of the receptor tyrosine kinase → activation of the RAS-MAPK, PI3K-Akt and JAK-STAT pathways → proliferation and malignant transformation of parathyroid cells (C cells). Anaplastic thyroid cancer arises either through dedifferentiation from a pre-existing differentiated thyroid cancer (PTC or FTC) or as anaplastic from the outset. Co-occurrence of BRAF V600E + TERT promoter mutations is strongly associated with transformation of differentiated thyroid cancer into anaplastic cancer. Loss of TP53 is the key event in the final anaplastic transformation.

6. Symptoms

Most thyroid cancers are asymptomatic early and are found incidentally on ultrasound screening or during testing for other conditions. When symptomatic, a neck mass (cervical nodule) is the most common complaint, characteristically a painless nodule that grows slowly over weeks to months. When the nodule is large or invades surrounding structures, dysphagia, hoarseness—due to invasion of the vocal cord nerve (recurrent laryngeal nerve, RLN)—, dyspnea and chronic cough may occur.

In medullary thyroid cancer, diarrhea (especially with severe hypercalcitoninemia) and facial flushing due to calcitonin secreted by tumor cells are characteristic symptoms. In MEN2A, in addition to thyroid nodules, symptoms of hyperparathyroidism (hypercalcemia, kidney stones) and pheochromocytoma (headache, palpitations, sweating, hypertensive crises) may be present. With cervical lymph node metastasis, cervical lymphadenopathy is palpable, and with distant metastasis (lung, bone, liver), symptoms of the affected organ (dyspnea, bone pain, jaundice) occur. Anaplastic thyroid cancer progresses rapidly, with a fast-growing, hard, fixed neck mass along with neck pain, dyspnea and dysphagia.

7. Signs

Malignancy is suspected when thyroid palpation reveals a firm, irregular-surfaced, fixed thyroid nodule. Adhesion of the nodule to the neck skin or surrounding tissue is also a sign of malignancy. When cervical lymphadenopathy—especially central (level VI) or lateral neck lymph nodes—is found together with a thyroid nodule, accompanying metastasis is likely. Vocal cord paralysis due to recurrent laryngeal nerve palsy is confirmed by laryngoscopy and is a sign of local progression of thyroid cancer. With tracheal compression, stridor is heard on auscultation.

In medullary thyroid cancer and MEN2A, hypertension (with accompanying pheochromocytoma) and signs of hypercalcemia (with accompanying parathyroid tumor) appear. With bone metastasis, spinal tenderness and neurologic deficits are found. In anaplastic thyroid cancer, rapid neck enlargement is observed along with tracheal deviation and neck vein distension due to jugular vein compression. Thyroid function is usually normal (thyroid cancer itself rarely causes hormone hypersecretion), but functional changes are possible with extensive involvement.

8. Screening

Korea is a country where thyroid ultrasound screening is performed very widely. Although the thyroid is not included in the national screening program for the 5 major cancers (stomach, colorectum, liver, cervix, breast), many medical institutions and health screening centers offer thyroid ultrasound as a non-covered service. The resulting overdiagnosis problem has been controversial in academia, and debate continues in particular over whether to actively treat papillary thyroid microcarcinoma (microPTC) of 5 mm or less.

K-TIRADS (Korean Thyroid Imaging Reporting and Data System) classifies thyroid nodules into 5 categories (K-TIRADS 1–5) according to ultrasound findings and sets FNA criteria by nodule size. FNA is recommended for K-TIRADS 4 (low suspicion) at 1 cm or larger and for K-TIRADS 5 (high suspicion) at 0.5 cm or larger. In families with hereditary medullary thyroid cancer (MEN2 families), screening by RET gene testing is standard, and when a variant is confirmed, the timing of prophylactic thyroidectomy is determined. For thyroid ultrasound screening in the general population, shared decision-making based on the benefit-harm balance and individual physician and patient preference is recommended.

9. Diagnosis

The standard sequence for diagnosing thyroid cancer is thyroid ultrasound → fine-needle aspiration cytology (FNA) → molecular testing (if needed). Thyroid ultrasound assesses nodule size, shape, margins, echogenicity (hypoechoic), calcification (microcalcification), intratumoral blood flow and cervical lymph node status, applying the K-TIRADS classification. Ultrasound-guided fine-needle aspiration cytology (US-FNA) obtains an adequate specimen for a cytologic diagnosis using the Bethesda classification (I–VI). In Bethesda III–IV (indeterminate/follicular neoplasm), adding molecular testing (multigene panels such as ThyroSeq v3 and ThyGeNEXT) allows more accurate stratification of malignancy risk.

Single BRAF V600E testing helps confirm malignancy risk and plan surgery in Bethesda V–VI nodules. Thyroid function tests (TSH, Free T4, T3) and thyroid autoantibodies (Anti-TPO, Anti-Tg) are performed in parallel. When medullary thyroid cancer is suspected, measurement of serum calcitonin and CEA and RET gene mutation testing are essential. After malignancy is confirmed, neck and chest CT and, if needed, bone scan and FDG-PET-CT are performed for staging. Laryngoscopy to assess vocal cord function before surgery is also important.

10. Treatment

The standard treatment for differentiated thyroid cancer (papillary and follicular) is total thyroidectomy or hemithyroidectomy (for low-risk small tumors). With cervical lymph node metastasis or in high-risk cases, central neck dissection is also performed. After surgery, radioactive iodine (RAI, I-131) therapy is used in high-risk groups for ablation of remnant thyroid tissue and treatment of metastases. TSH suppression therapy—maintaining serum TSH at 0.1 mU/L or below with levothyroxine (L-T4)—is used to suppress recurrence.

In radioactive iodine-refractory (RAI-refractory) differentiated thyroid cancer, lenvatinib and sorafenib are first-line standard treatments. In RET variant/fusion thyroid cancer (including medullary and papillary), selpercatinib and pralsetinib have been approved. In NTRK fusion thyroid cancer, larotrectinib and entrectinib are indicated. In BRAF V600E-positive anaplastic thyroid cancer, dabrafenib+trametinib showed a 56% response rate and is becoming established as first-line treatment, and PD-1/PD-L1 inhibitor combination therapy is under study in BRAF-negative ATC. In MTC, cabozantinib and vandetanib are second-line options.

11. Prognosis

The prognosis of thyroid cancer differs very greatly by histologic type. Papillary thyroid cancer has the best prognosis, with a 5-year overall survival rate of more than 95%, and a 10-year survival rate of more than 90% for localized disease. Even with distant metastasis, long-term survival is possible with RAI-sensitive lesions. The 5-year survival rate of follicular thyroid cancer is about 90% but drops when distant metastasis occurs. The 5-year survival rate of medullary thyroid cancer is about 75–80%, and prognosis is better with prophylactic surgery in hereditary (MEN2) than in sporadic cases.

Anaplastic thyroid cancer has the poorest prognosis and is highly lethal, with a median survival of 3–9 months after diagnosis and a 1-year survival rate of less than 10%. In BRAF V600E-positive ATC, dabrafenib+trametinib improved the overall response rate to 56% and median overall survival to about 14.5 months, but the outlook remains poor. Important prognostic factors include histologic type, stage (TNM), age (worse at 45 and older), extent of resection, distant metastasis, RAI uptake capacity, and BRAF/TERT co-mutation (increased recurrence risk).

12. Prevention

Minimizing radiation exposure is central to preventing thyroid cancer. In the event of a nuclear accident, prophylactic administration of stable iodine (potassium iodide) and thyroid shielding are important to prevent inhalation of radioactive iodine, especially in children. Medical radiation (CT, radioisotope studies) should be used only for clear clinical indications, and unnecessary head and neck radiation exposure should be avoided, especially in children. Iodine supplementation can contribute to preventing follicular and anaplastic thyroid cancers in deficient areas; Korea is an iodine-sufficient area, so excessive iodine intake may instead cause thyroid dysfunction.

In families with hereditary medullary thyroid cancer (MEN2), the best prevention is to identify variant carriers through RET gene testing and perform early prophylactic total thyroidectomy according to risk. For the MEN2B (Met918Thr) variant, surgery within the first 6 months of life is recommended. Regular thyroid screening is also recommended for carriers of Cowden syndrome (PTEN mutation) and patients with FAP (APC mutation). When a thyroid nodule is found, appropriate follow-up and FNA according to K-TIRADS criteria to detect and treat malignant nodules early are important for improving prognosis.


13. References

  1. National Cancer Information Center. Thyroid cancer incidence statistics. 2024.
  2. Ahn HS, et al. Increasing thyroid cancer rate and extent of surgery in Korea. PMC. 2014;PMC4254284.
  3. Haugen BR, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and thyroid cancer. Thyroid. 2016;26(1):1-133.
  4. TERT promoter and BRAF V600E mutations in Korean PTC. PMC. 2022;PMC9563418.
  5. Dabrafenib plus trametinib in BRAF V600E-mutated ATC. PMC. 2022;PMC9338780.
  6. Wirth LJ, et al. Selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020;383(9):825-835.
  7. Lenvatinib therapy for thyroid cancer. Pharmaceuticals. 2025.
  8. K-TIRADS 2021 revised edition. Korean Society of Thyroid Radiology, 2021.